JF reports consulting fees from Lundbeck, Ionis, and AC immune; reports speaker honoraria from Roche, Esteve, Biogen, Laboratorios Carnot, Adamed, Life Molecular Imaging, Eisai, and Lilly; serves on the advisory boards or adjudication committees for AC Immune, Alzheon, Zambón, Lilly, Roche, Eisai, and Perha; holds a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, EPI8382175.0); has leadership or fiduciary roles in the Spanish Neurological Society, T21 Research Society, LuMind Foundation, Jérôme-Lejeune Foundation, Alzheimer's Association, Health Research Board, Dementia Trials Ireland, European Commission, National Institutes of Health USA, and Instituto de Salud Carlos III; is in receipt of equipment to his institution from Life Molecular Imaging; and reports support from Fondo de Investigaciones Sanitario, Instituto de Salud Carlos II, National Institutes of Health USA, Generalitat de Catalunya, Fundació Tatiana Pérez de Guzmán el Bueno, Alzheimer's Association, BrightFocus, and Horizon 2020. MB reports institutional research grants from the 4BrainFlames project (EU funded) and Croatian Science Foundation. SE reports consulting fees from Biogen, Eisai (paid to institution), Icometrix (paid to institution), Janssen, Eli Lilly, Novartis (paid to institution), and Roche; holds patent EP3452830B1 for an assay for the diagnosis of a neurological disease (licensed to ADX Neurosciences NV and Euroimmun Medizinische Labordiagnostika); serves as an unpaid member of the safety monitoring and advisory board for EU-H2020 project RECAGE and of the data and safety monitoring board of PRImus-AD, all unpaid; is Co-Chair of the Dementia and Cognitive Disorders scientific panel for the European Academy of Neurology (unpaid); is Co-Chair of the European Alzheimer's Disease Consortium (unpaid); and is Vice President of the Belgian Dementia Council (unpaid). KSF reports research grants managed by his institution from AP Møller Fonden, Danish Alzheimer Foundation, IHI EU, and ERA-PER-MED; royalties as an editor on a book for Springer Nature and as a contributor to a book for Hans Reitzel Publishing; consulting fees paid to his institution from Eli Lilly and Eisai/Bioarctic; honoraria paid to his institution from Eli Lilly, Eisai/Bioarctic, and Novo Nordisk, and personal remuneration from Dagens Medicin; participation on advisory boards for Roche Diagnostics and Novo Nordisk with fees paid to his institution; being an unpaid Co-Chair of the Guideline Production Group for the European Academy of Neurology; and personal remuneration as Editor-in-Chief of Alzheimer's Research & Therapy from Springer Nature. JH reports consulting fees from Eli Lilly and Eisai; speaker honoraria from Eli Lilly and Schwabe; payment from Eisai for expert testimony at a Committee for Medicinal Products for Human Use meeting on lecanemab; support for attending meetings from Novo Nordisk and Eli Lilly; and ownership of stock and stock options in Alzheon. SK reports consulting fees from Eisai; honoraria for lectures and presentations from Sanofi; and participation on an advisory board for Eisai, all unrelated to this Correspondence. MGK reports a research grant managed by her institution from PROMINENT; and honoraria for lectures from Eli Lilly paid to her institution. DP reports a research grant from the Italian Ministry of Health Young Researcher Project (GR-2021-12372306), with payments made to the University of Siena; and has received support for attending meetings from Fujirebio Italia, with travel expenses paid in 2024 and 2025. CP reports participation in international and national boards and consulting for Eli Lilly, Eisai, Novo Nordisk, UCB, and Roche. IS reports consulting fees from Eisai and Lilly; honoraria for lectures and presentations from Eli Lilly and Novo Nordisk; support for attending meetings from Eli Lilly, Lundbeck, and Sanofi; and participation on an advisory board for Novo Nordisk. NS reports institutional research funding from Novo Nordisk as a local principal investigator for a multicenter phase 3 Alzheimer's disease trial. ES reports receiving institutional research funding from Wihuri Foundation, the State Research Funding, Roche, Sigrid Juselius Foundation, EU-Horizon, the Research Council of Finland, Jane and Aatos Erkko Foundation, Orion, and the Finnish Medical Foundation; provided consultancy to Novo Nordisk, BioArctic, Eisai, Lilly, and Roche; received honoraria for lectures from Lundbeck, BioArctic, and Roche; received travel support from Lilly; and served on advisory boards for Novartis, Eisai, Eli Lilly, and Roche. LS reports consulting fees from Sanofi Pharma (personal and institutional); speaker honoraria from Sanofi Pharma, Ever Pharma, and Sunwave Pharma; participation on a scientific advisory board of Sanofi Pharma; and a leadership role at Sanofi Pharma. EGBV reports research funding managed by his university as a principal investigator for studies sponsored by DIAN, AC Immune, Alnylam, CogRx Therapeutics, New Amsterdam Pharma, Janssen, UCB, Roche, Vivoryon, ImmunoBrain, GSK, MSD, Biogen, Alector, Eli Lilly, AriBio, Fujifilm Toyama, and GemVax; has received consultancy fees (paid to his university) from New Amsterdam Pharma, Treeway, ReMynd, Vivoryon, Biogen, Vigil Neuroscience, ImmunoBrain Checkpoint, Muna Therapeutics, Eisai, Eli Lilly, CogRx, Therini, UCB, and Roche; and has received honoraria for lectures from Eli Lilly and Biogen (paid to his institution). BW serves as a member of the scientific advisory boards of Alzinova, Axon Neuroscience, Artery Therapeutics, and Phanes Biotech; serves as a member of the data safety monitoring board for Primus-AD; and holds stock in Artery Therapeutics and AlzeCure. FJ reports grants from Roche; consulting fees from Eisai, Eli Lilly, Biogen, AbbVie, Roche, and Grifols; personal fees for advice and presentation from Eisai, Eli Lilly, Biogen, AbbVie, Roche, Janssen, and GH Healthcare; personal fees for expert testimony from Eli Lilly and Eisai at the Committee for Medicinal Products for Human Use hearings on donanemab and lecanemab; and participation on a data safety monitoring board or advisory board for AC Immune. All other authors declare no competing interests.